PDCD1 and cancer: With the use of CB-1158, it may provide bioavailable arginine for T cell activation, and the combination use of pembrolizumab can block PD-1 and PD-L1 ligation, thus abrogating inhibitory signals, which together may enhance T cell-mediated anti-cancer activities.